SensNews April 2020

Sensor100 2020 18 Interpreting the Results This survey was a first attempt to solicit the views of the sensor community on a num- ber of issues relevant to forecasting what would be the main applications of biosensors in ten years time - the year 2030. The on-line and conference questionaires were answered by approximately 100 people who self-qualified their expertise in the range 3-5 (1= "not very" expert; 5 = "Totally" expert). Our intention was to test the conclusions of this survey on a much wider audience. However, the current coronavirus pandemic makes this course unfeasible: (1) most people are too preoccupied to answer questionaires, except on the virus and (2) it is likely that the results of the second survey would be heavily biased. From the limited data we obtained there were some indications although they may be influenced by the people interested in Sensors in Medicine Conferences. AI andWearables were projected as th leading technologies in 2030. Cancer and Cardiovascular disease were projected to be the leading diseases diag- nosed by sensor biomarkers in 2030, with infectious diseases in third place - a survey today would probably place IDs as a clear lead. Blood and Saliva were the most forecast bodily fluids for testing. About the Respondents Occupations: Academic research 74% Medical device company 22% Other 04% Respondents who agreed to our publishing their support: David Attwood | Katherine Boylan | Cecilia Cristea | Nikolas Daskalkis Paul Stephen Gascoine | Mohsen Golabi | Oliver Hayden | Onur Parlak Samadhan Patil | Teena Rajan | Tania Read | Julien Reboud | JohnWitton Sensor 100 extends its thanks to the above supporters of the project, as well as all the others who preferred to remain anonymous. This project would not have taken place without the generous support of LifeArc.